がん精巣抗原治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:CancerTestis Antigen 1 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0495
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥371,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥742,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,113,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

CancerTestis Antigen 1 – Pipeline Review, H2 2019
Summary

According to the recently published report ‘CancerTestis Antigen 1 – Pipeline Review, H2 2019′; Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine.

The report ‘CancerTestis Antigen 1 – Pipeline Review, H2 2019′ outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 6 and 5 respectively. Similarly, the universities portfolio in Phase I stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Metastatic Melanoma, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Anaplastic Astrocytoma, Bladder Cancer, Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Peritoneal Cancer, Synovial Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Scope

- The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Overview
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Companies Involved in Therapeutics Development
Aduro BioTech Inc
Beijing Biohealthcare Biotechnology Co Ltd
Boehringer Ingelheim International GmbH
Cynvec LLC
GlaxoSmithKline Plc
Immunocore Ltd
Immunomic Therapeutics Inc
iOx Therapeutics Ltd
Merck & Co Inc
Sanofi Pasteur SA
Sapvax LLC
Scancell Holdings Plc
Vault Pharma Inc
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Drug Profiles
ADU-623 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CTAG1B for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYN-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy to Inhibit NY-ESO-1 for Advanced Malignancy and Multiple Myeloma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2241658A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3537142 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-65 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-7000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCIB-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SVX-ESO – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CTAG1A for Gastric Cancer and Hepatocellular Carcinoma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCP-2292 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Dormant Products
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Discontinued Products
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) – Product Development Milestones
Featured News & Press Releases
May 20, 2019: Scancell and Cancer Research UK provide an update on the development of SCIB2, a novel cancer immunotherapy
Apr 29, 2019: $4.6 million grant funds clinical trial of stem cell immunotherapy for metastatic sarcoma and other hard-to-treat cancers
Apr 02, 2019: Immunomic Therapeutics presents late-breaking preclinical data on DNA vaccine ITI-7000 at AACR 2019
Feb 28, 2019: Immunomic Therapeutics announces late-breaking presentation at the American Association for Cancer Research Annual Meeting 2019
Oct 11, 2018: Immune Design provides update on CMB305 cancer vaccine
Oct 01, 2018: Hitachi Chemical Advanced Therapeutics Solutions signs three-year agreement with GSK to provide clinical manufacturing for T cell therapy
Aug 21, 2018: Immunocore doses first patient in Phase I trial of IMCnyeso
May 24, 2018: Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Improvement in Survival for CMB305 Monotherapy in Sarcoma
Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress
Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe
Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting
Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aduro BioTech Inc, H2 2019
Pipeline by Beijing Biohealthcare Biotechnology Co Ltd, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Cynvec LLC, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Immunocore Ltd, H2 2019
Pipeline by Immunomic Therapeutics Inc, H2 2019
Pipeline by iOx Therapeutics Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Sanofi Pasteur SA, H2 2019
Pipeline by Sapvax LLC, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by Vault Pharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

Aduro BioTech Inc
Beijing Biohealthcare Biotechnology Co Ltd
Boehringer Ingelheim International GmbH
Cynvec LLC
GlaxoSmithKline Plc
Immunocore Ltd
Immunomic Therapeutics Inc
iOx Therapeutics Ltd
Merck & Co Inc
Sanofi Pasteur SA
Sapvax LLC
Scancell Holdings Plc
Vault Pharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[がん精巣抗原治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆